Evofem Biosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Evofem Biosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $16.84M | Apr 27, 2023 |
| FY2022 | Dec 31, 2021 | $8.24M | Apr 27, 2023 |
| FY2021 | Dec 31, 2020 | $446.0K | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 4, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.18M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $19.36M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $18.22M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $16.84M | Mar 27, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $391.0K | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($8.86M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $52.98M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($76.70M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($205.19M) | Apr 27, 2023 |
| FY2021 | Dec 31, 2020 | ($142.31M) | Mar 10, 2022 |
| FY2019 | Dec 31, 2019 | ($12.72M) | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | ($13.80M) | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | ($35.45M) | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | ($18.07M) | Mar 12, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.37M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($7.68M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | ($17.85M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($84.12M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($166.80M) | Apr 27, 2023 |
| FY2021 | Dec 31, 2020 | ($103.62M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($52.74M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($77.64M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($35.69M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($12.04M) | Feb 26, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.27M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $23.79M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $10.55M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $25.16M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $42.51M | Apr 27, 2023 |
| FY2021 | Dec 31, 2020 | $109.97M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $28.30M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $4.01M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $3.95M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $12.82M | Feb 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.71M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $90.26M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $72.47M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $96.96M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $142.09M | Apr 27, 2023 |
| FY2021 | Dec 31, 2020 | $108.62M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $12.66M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $27.37M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $103.63M | Mar 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($74.34M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($71.26M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | ($66.51M) | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | ($71.80M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | ($104.32M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $1.35M | Apr 27, 2023 |
| FY2021 | Dec 31, 2019 | $15.64M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | ($23.36M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | ($289.55M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | ($181.09M) | Mar 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 10 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (167) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | (23) | Apr 27, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 10, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (167) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | (23) | Apr 27, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 10, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $578.0K | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $741.0K | Mar 11, 2026 |
| FY2023 | Dec 31, 2022 | $2.77M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $7.73M | Apr 27, 2023 |
| FY2021 | Dec 31, 2020 | $48.89M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $15.57M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $1.33M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $1.21M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $11.48M | Feb 26, 2018 |
| FY2017 | Dec 31, 2015 | $37.75M | Feb 26, 2018 |